Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

FASEB Journal

Volumn 10, Issue 8, 1996, Pages 905-912

  Sato, Masahiko ^a   Rippy, Marian K ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

bone; cholesterol; osteoclast; osteoporosis; uterus

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; NAFOXIDINE; RALOXIFENE; TAMOXIFEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; FEMALE; HISTOPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; TISSUE SPECIFICITY;

EID: 0029994748     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.10.8.8666168     Document Type: Article

References (45)

1. Weiss, N. S., Ure, C. L., Ballard, J. H., Williams, A. R., and Daling, J. R. (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N. Engl. J. Med. 303, 1195-1198
2. Lindsay, R., Hart, D. M., Forrest, C., and Baird, C. (1980) Prevention of spinal osteoporosis in oopherectomized women. Lancet 2, 1151-1154
3. Quigley, M. E. T., Martin, P. L., Curnier, A. M., and Brooks, P. (1987) Estrogen therapy arrests bone loss in elderly women.Am. J. Obstet. Gynecol. 156, 1516-1523
4. Moore, M., Bracker, M., and Sartoris, D. (1990) Long-term estrogen replacement therapy in postmenopausal women sustains vertebral bone mineral density. J. Bone Miner. Res. 5, 659-664
5. Christiansen, C. (1992) Prevention and treatment of osteoporosis - a review of current modalities. Bone 13, S35-S39
6. Felson, D., Zhang, Y., Hannan, M., Kiel, D., Wilson, P., and Anderson, J. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329, 1141-1146
7. Dempster, D. W., and Lindsay, R. (1993) Pathogenesis of osteoporosis. Lancet 341, 797-801
8. Lindsay, R. (1993) Prevention and treatment of osteoporosis. Lancet 341, 801-805
9. Ziel, H. K., and Finkle, W. D. (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med. 293, 1167-117010
10. Smith, D. C., Prentice, R., Thompson, D. J., and Herrmann, W. L. (1975) Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293, 1164-1167
11. Vesey, M. P. (1984) Exogenous hormones in the aetiology of cancer in women. J. R. Soc. Med. 77, 542-549
12. Steinberg, K. K., Thacker, S. B., and Smith, S. C. (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J. Am. Med. Assn. 265, 1985-1990
13. Dupont, W. D., and Page, D. L. (1991) Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 151, 67-72
14. Hammond, C. B., Jelovsek, F. R., Lee, K. L., Creasman, W. T., and Parker, R. T. (1979) Effects of long term estrogen therapy. I. Metabolic effects. Am. J. Obstet. Gynecol. 133, 525-536
15. Burch, J. C., Byrd, B. F., and Vaughn, W. K. (1974) The effects of long-term estrogen on hysterectomized women. Am. J. Obstet. Gynecol. 118, 778-782
16. + health study. N. Engl. J. Med. 325, 756-762
17. Devor, M., Barrett-Conner, E., Renvall, M., Feigal, D., and Ramsdell, J. (1992) Estrogen replacement therapy and the risk of venous thrombosis. Am. J. Med. 92, 275-282
18. Sunderland, M. C., and Osborne, C. K. (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. Clin. Oncol. 9, 1283-1297
19. Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., and DeMets, D. L. (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Int. Med. 115, 860-864
20. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and DeMets, D. L. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326, 852-856
21. Kedar, R. P., Bourne, T. H., Powles, T. J., Collins, W. P., Ashley, S. E., Cosgrove, D. O., and Cambell, S. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343, 1318-1321
22. Draper, M. W., Flowers, D. E., Huster, W. J., and Neild, J. A. (1993) Effects of raloxifene (LY139481 HCl) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In Proceedings of the 4th International Symposium on Osteoporosis, pp. 119-121, Hong Kong (abstr.)
23. Kalu, D. N. (1991) Review: The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15, 175-192
24. Wronski, T. J., and Yen, C. F. (1991) The ovariectomized rat as a animal model for postmenopausal bone loss. Cell Mater. S1, 69-74
25. Frost, H. M., and Jee, W. S. S. (1992) On the rat model of human osteopenias and osteoporoses. Bone Miner. 18, 227-236
26. Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., Bensch, W. R., Frolik, C., Termine, J., and Bryant, H. U. (1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertropy in ovariectomized rats. J. Clin. Invest. 93, 63-69
27. Sato, M., McClintock, C., Kim, J., Turner, C., Bryant, H., Magee, D., and Slemenda, C. (1994) Dual-Energy X-ray Aborptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 9, 715-724
28. Jordan, V. C., Allen, K. E., and Dix, C. J. (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep. 64, 745-759
29. Turner, R. T., Wakley, G. K., Hannon, K. S., and Bell, N. H. (1988) Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122, 1146-1150
30. Kalu, D. N., Salerno, E., Liu, C. C., Echon, R., Ray, M., Garza-Zapata, M., and Hollis, B. W. (1991) A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner. 15, 109-124
31. Moon, L. Y., Wakley, G. K., and Turner, R. T. (1991) Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian status. Endocrinology 129, 1568-1574
32. Katzenellenbogen, B. S., Bhakoo, H. S., and Ferguson, E. R. (1979) Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog. Horm. Res. 35, 259-300
33. Galand, P., Tchernitchin, N., and Tchernitchin, A. N. (1984) Time-course of the effects of nafoxidine and estradiol on separate groups of responses in the uterus of the immature rat. J. Steroid Biochem. 21, 43-48
34. Black, L. J., Jones, C. D., and Facone, J. R. (1983) Antagonism of estrogen action with a new henzothiophene derived antiestrogen. Life Sci. 32, 1031-1036
35. Sato, M., Kim, J., Short, L. L., Slemenda, C. W., and Bryant, H. U. (1995) Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 272, 1252-1259
36. Salo, M. (1995) Comparative X-ray densitometry of bones from ovariectomized rats. Bone 17, 157S-162S
37. Cray, J. M., and Wade, G. N. (1981) Food intake, body weight, and adiposity in female rats: actions and interactions of progestins and antiestrogens. Am J. Physiol. 240, E474-E81
38. Wade, C. N., and Heller, H. W. (1993) Tamoxifen mimics the effects of estradiol on food intake body weight, and body composition in rats. Am J. Physiol. 264, R1219-R1223
39. Kalu, D. N., Liu, C. C., Salerno, E., Hollis, B., Echon, R., and Ray, M. (1991) Skeletal response of ovariectomized rats to low and high doses of 17 β-estradiol. Bone Milter. 14, 175-187
40. Lyttle, C. R., and DeSombre, E. R. (1977) Uterine peroxidase as a marker for estrogen action. Proc. Natl. Acad. Sci. USA 74, 3162-3166
41. White, S. R., Kulp, V. P., Spaethe, S. M., Van Alstyne, E. L., and Leff, A. R. (1991) A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media. J. Immunol. Methods 44, 257-263
42. Crynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) A new generation of Ca indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450
43. Dukes, M., Chester, R., Yarwood, L., and Wakeling, A. E. (1994) Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. J. Endocrinol. 141, 335-341
44. Fuchs-Young, R., Magee, D. E., Cole, H. W., Short, L., Glasebrook, A., Rippy, M. K., Termine, J. D., and Bryant, H. U. (1995) Raloxifene is a tissue-specific antiestrogen that blocks tamoxifen or estrogen-stimulated uterotrophic effects. Program of the 77th Annual Meeting of The Endocrine Society, pp. 57, Washington, D.C. (abstr.)
45. McDonnell, D. P., Clemm, D. L., Hermann, T., Goldman, M. E., and Pike, J. W. (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9, 659-669